Reduced serum progranulin level might be associated with Parkinson's disease risk
Article first published online: 9 FEB 2013
© 2013 The Author(s) European Journal of Neurology © 2013 EFNS
European Journal of Neurology
Volume 20, Issue 12, pages 1571–1573, December 2013
How to Cite
Mateo, I., González-Aramburu, I., Pozueta, A., Vázquez-Higuera, J. L., Rodríguez-Rodríguez, E., Sánchez-Juan, P., Calero, M., Dobato, J. L., Infante, J., Berciano, J. and Combarros, O. (2013), Reduced serum progranulin level might be associated with Parkinson's disease risk. European Journal of Neurology, 20: 1571–1573. doi: 10.1111/ene.12090
- Issue published online: 8 NOV 2013
- Article first published online: 9 FEB 2013
- Manuscript Accepted: 29 NOV 2012
- Manuscript Received: 14 AUG 2012
- CIEN Foundation. Grant Number: PI019/09
- CIBERNED. Grant Number: CB06/07/0037
- Alzheimer's disease;
- Parkinson's disease;
- risk factor;
Background and purpose
Common genetic variants (rs5848 and rs646776) have been reported as regulators of blood progranulin (GRN) levels in healthy individuals.
To assess the influence of rs5848 and rs646776 polymorphisms in both serum GRN level and risk for common neurodegenerative diseases, we studied 304 patients with Parkinson's disease (PD), 217 individuals with Alzheimer's disease, 131 subjects with mild cognitive impairment, and 126 controls.
The mean concentration of GRN in the serum of patients with PD (319.6 ng/ml) was significantly lower than that of controls (371.5 ng/ml; P = 0.009), whereas there were no significant differences between other groups. Rs646776 minor allele carriers had lower serum GRN levels in each of the four subgroups. There was no correlation between rs5848 genotypes and serum GRN concentrations. Genotype frequencies of both polymorphisms did not differ between groups.
Reduced circulating GRN levels might be associated with PD risk by pathogenic factors different from rs5848 and rs646776 polymorphisms.